A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.
A recent study in the Journal of Investigative Dermatology identified potential early factors in the development of hidradenitis suppurativa, involving apocrine gland damage and keratin release, offering insights into potential biomarkers for disease severity and progression.